Related Experiment Videos
The urokinase plasminogen activator system: role in malignancy
1Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland. Michael.J.Duffy@ucd.ie
Current Pharmaceutical Design
|February 3, 2004
Summary
The urokinase plasminogen activator (uPA) system and its inhibitor PAI-1 are key in breast cancer progression. Measuring uPA/PAI-1 levels can identify low-risk patients, potentially avoiding unnecessary chemotherapy.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- The urokinase plasminogen activator (uPA) system, comprising uPA, uPAR, PAI-1, and PAI-2, is implicated in cancer progression.
- uPA plays roles in extracellular matrix remodeling, cell proliferation, migration, and adhesion.
- Elevated uPA levels in primary breast cancers correlate with adverse outcomes.
Purpose of the Study:
- To investigate the prognostic value of the uPA system, specifically uPA and PAI-1, in breast cancer.
- To determine if uPA/PAI-1 assays can identify low-risk patients eligible for reduced adjuvant therapy.
Main Methods:
- Analysis of uPA and PAI-1 levels in breast cancer patients.
- Validation using prospective randomized trials and pooled analyses (Level 1 Evidence).
- Preclinical studies involving inhibition of uPA activity or uPA-uPAR binding.
Main Results:
- High uPA levels are independently associated with poor prognosis in breast cancer.
- High PAI-1 levels also correlate with poor prognosis.
- Prognostic value of uPA/PAI-1 validated in axillary node-negative patients.
- Preclinical data show inhibition of uPA pathway reduces tumor growth, angiogenesis, and metastasis.
Conclusions:
- Assaying uPA and PAI-1 can identify low-risk, node-negative breast cancer patients.
- This may help spare patients from unnecessary adjuvant chemotherapy.
- Targeting the uPA system presents a potential therapeutic strategy for breast cancer.